ASX copper stocks have recorded 3 big hits this week

Nick Sundich Nick Sundich, November 4, 2022

ASX copper stocks have not been as popular with investors as lithium stocks recently. Copper has been plagued by China’s COVID zero policy and rising interest rates. But there have been some notable hits made by ASX copper explorers this week.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Norfolk Metals leads the charge

Tasmanian-focused explorer Norfolk Metals (ASX:NFL) yesterday reported the intersection of native copper in the maiden drill test at its Roger River Project.

These were not formal assay results, these are coming in December. But the company did intersect visible copper and, in doing so in the first drilling hole, shareholders hope that further results will continue to deliver.

 

Other ASX copper hits this week 

Another solid result from an ASX copper stock came from American West (ASX:AW1). The Canadian focused explorer recorded assay results of 19m @ 2.08%, including 2m at 15.98% copper.

And this morning, Cosmo Metals (ASX:CMO) reported results from its Mt. Venn project in Western Australia: 13m @ 0.46% copper, including 1m @ 1.27% copper. Typically, any copper grade below 1.3% is considered lower grade. But it appears shareholders are willing to forgive this given WA’s lower sovereign risk.

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

Recent Posts

buy nvidia shares in australia

Should you buy Nvidia shares in Australia?

Many investors are likely wondering if they should buy Nvidia shares in Australia? Others still might be wondering just who…

ASX:MSB

Mesoblast (ASX:MSB): Will it thrive or just survive in 2024?

Mesoblast’s (ASX:MSB) struggle with regenerative medicine in 2023 involved kеy financial movеs as wеll as opеrational rеstructurings. Thе entity which…

Star Entertainment Group … the house doesn’t always win

Thе recently released 2023 annual rеport of Star Entertainment Group portrays an intricatе fiscal position featuring extensive debt rеduction, but…